MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: We find that mTOR signaling pathway is upregulated in tRCC tumor tissues in both proteome and phosphoproteome levels, which indicates mTOR signaling is a potential therapeutic target.